S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial
S-1联合伊立替康加贝伐单抗对比mFOLFOX6或CapeOX联合贝伐单抗作为转移性结直肠癌患者一线治疗方案(TRICOLORE):一项随机、开放标签、III期非劣效性试验
期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdx816
Yamada, Y; Denda, T; Gamoh, M; Iwanaga, I; Yuki, S; Shimodaira, H; Nakamura, M; Yamaguchi, T; Ohori, H; Kobayashi, K; Tsuda, M; Kobayashi, Y; Miyamoto, Y; Kotake, M; Shimada, K; Sato, A; Morita, S; Takahashi, S; Komatsu, Y; Ishioka, C